追风透骨胶囊治疗膝骨关节炎(寒湿痹阻证):随机双盲多中心临床研究
本研究为随机、平行对照、双盲、双模拟多中心试验,纳入215例寒湿痹阻证膝骨关节炎患者,1:1随机分为追风透骨胶囊组(107例)和硫酸氨基葡萄糖胶囊组(108例),治疗12周。结果显示追风透骨胶囊在改善WOMAC疼痛评分、VAS评分、WOMAC骨关节炎评分及中医证候评分方面显著优于对照组(P<0.01),且未出现严重不良反应。
要点
- 追风透骨胶囊可显著改善寒湿痹阻证膝骨关节炎患者的疼痛和关节功能。
- 疗效优于硫酸氨基葡萄糖胶囊,体现在WOMAC疼痛评分、VAS评分等指标(P<0.01)。
- 两组ESR、CRP及髌上囊积液深度无显著差异(P>0.05),安全性良好。
核心结论
- 追风透骨胶囊能有效改善膝骨关节炎患者的膝关节功能并显著缓解疼痛。
研究设计与样本
- 随机、平行对照、双盲、双模拟多中心临床试验,共纳入215例寒湿痹阻证膝骨关节炎患者,1:1随机分为试验组107例和对照组108例,治疗12周。
主要发现
- 两组治疗后WOMAC疼痛评分、VAS疼痛评分、自评VAS评分、WOMAC骨关节炎评分及中医证候评分均较治疗前显著下降(P<0.01)。
- 试验组在上述指标上显著优于对照组(P<0.01)。
- 治疗后两组ESR水平、CRP水平及髌上囊积液深度无显著差异(P>0.05)。
- 试验组和对照组均未出现严重不良反应。
关键数值与推荐
- 主要疗效指标为WOMAC疼痛评分。
- 次要疗效指标包括VAS疼痛评分、自评VAS评分、WOMAC骨关节炎评分、中医证候评分及中医证候疗效、ESR水平、CRP水平、髌上囊积液深度、解救药物使用及安全性指标。
- 试验组干预为追风透骨胶囊+硫酸氨基葡萄糖胶囊模拟剂,对照组为硫酸氨基葡萄糖胶囊+追风透骨胶囊模拟剂。
临床怎么用
- 对于寒湿痹阻证膝骨关节炎患者,可考虑使用追风透骨胶囊以改善疼痛和关节功能。
- 使用追风透骨胶囊时需辨证为寒湿痹阻证,并关注12周疗程的疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In Traditional Chinese Medicine (TCM) theory, cold dampness obstruction is one of the common syndromes of osteoarthritis. Therefore, in clinical practice, the main treatment methods are to dispel wind, remove dampness, and dissipate cold, used to treat knee osteoarthritis (KOA). This report describes a mulitercenter clinical study to assess Zhuifeng Tougu Capsule's efficacy and safety in the treatment of patients who are cold dampness obstruction syndrome in KOA, and to provide evidence-based medical for the rational use of Zhuifeng Tougu Capsules in clinical practice. METHODS: This randomized, parallel group controlled, double-blind, double dummy trial will include a total of 215 KOA patients who meet the study criteria. 215 patients underwent 1:1 randomisation, with 107 cases assigned the experimental group (Zhuifeng Tougu Capsules + Glucosamine Sulfate Capsules Simulator) and 108 assigned the control group (Glucosamine Sulfate Capsules + Zhuifeng Tougu Capsules Simulator). After enrolment, patients received 12 weeks of treatment. The main efficacy measure is the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain score. Visual analogue scale (VAS) pain score, Self-condition assessment VAS score, WOMAC KOA score, TCM syndrome score and TCM syndrome efficacy, ESR level, CRP level, suprapatellar bursa effusion depth, use of rescue drugs, and safety indicators are secondary efficacy indicators. RESULTS: Compared with before treatment, WOMAC pain score, VAS pain score, Self-condition assessment VAS score, WOMAC KOA score, and TCM syndrome score decreased significantly in both groups (P < 0.01). Also, the experimental group showed significant differences in the above indicators compared to control (P < 0.01). However, after treatment, no significant differences were showed in the ESR level, CRP level, and suprapatellar bursa effusion depth between the two groups (P > 0.05). No any serious adverse effects showed in the experimental group and control group. CONCLUSIONS: Zhuifeng Tougu Capsules can effectively improve knee joint function and significantly alleviate the pain of KOA. TRIAL REGISTRATION: Clinical trial registration was completed with the China Clinical Trial Registration Center for this research protocol (No. ChiCTR2000028750) on January 2, 2020.
引用
- Zhao L, Zhou S, Wang S, et al. Zhuifeng Tougu capsules in the treatment of knee osteoarthritis (cold dampness obstruction syndrome): a randomized, double blind, multicenter clinical study. Chin Med. 2024. PMID: 38273399. doi:10.1186/s13020-024-00880-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。